Silexion Therapeutics Corp. announced promising preclinical results for its second-generation RNA interference therapy, SIL-204, which demonstrates synergistic efficacy when used in combination with ...
Silexion Therapeutics completes initial study of SIL-204 in pancreatic cancer models, assessing tumor growth and metastasis. Results expected in March 2025. Silexion Therapeutics Corp. announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results